By integrating genomic profiling for tumor specimens before and after neoadjuvant treatment, we discerned that neoadjuvant immunochemotherapy cased no significant alteration of the genomic landscape and demonstrated that the remaining tumor cells could still be sensitive to corresponding EGFR-TKIs in vitro. Here, EGFR is linked to neoplasm.